Congratulations to BC Renal executive director Dr. Adeera Levin for having an editorial published in the New England Journal of Medicine (NEJM) on the topic of anemia therapy for chronic kidney disease.
To follow is the opening of the editorial and a link to the full piece.
T
herapy for Anemia in Chronic Kidney Disease — New Interventions and New Questions
"Anemia, including its causes and treatments, in patients with chronic kidney disease (CKD) has been a focus of research for 40 years. Huge strides were made when erythropoietin was discovered and injectable erythropoiesis-stimulating agents (ESAs) were developed, followed by the conduct of randomized, controlled clinical trials that changed clinical practice. Multiple trials in which various ESAs have been compared with placebo or with each other have tested hypotheses about the value of targeting higher hemoglobin levels in patients with CKD. Such investigations showed variable signals for benefit (e.g., a reduced need for transfusions or improved quality of life) but also signals for harm (e.g., increased thrombosis of arteriovenous fistulas, stroke, and cancer-associated mortality).1-5"
More/full editorial: Therapy for Anemia in Chronic Kidney Disease — New Interventions and New Questions | NEJM
About the New England Journal of Medicine:
The New England Journal of Medicine is recognized as the world's leading medical journal and website. Published continuously for over 200 years, NEJM delivers high-quality, peer-reviewed research and interactive clinical content to physicians, educators, researchers, and the global medical community. More
